David Elia (1) / Marco Gambacciani (2) / Nicolas Berreni (1) / Jean Marc Bohbot (1) / René Druckmann (1) /Hugues Geoffrion (1) / Haab François (1) / Heiss Niko (1) / Nicolas Rygaloff (1) / Eleonora Russo (2)
Genitourinary syndrome of menopause (GSM) and laser VEL: a review
1 Vela-France (Vaginal Erbium Laser Academy France), Paris, France, E-mail: email@example.com
2 Vela-Italia (Vaginal Erbium Laser Academy Italia), Pisa, Italy
The purpose of this publication is to summarize the results of the vaginal erbium:yttrium-aluminum-garnet (Er:YAG) Smooth® laser (VEL) on the vaginal atrophy component of the genitourinary syndrome of menopause (GSM). GSM has two categories of clinical signs related to estrogen deficiency: symptoms of vulvovaginal atrophy (VVA) and urinary symptoms. This symptomatology is chronic, progressive over the years and affects a majority of women concerned by natural menopause but not exclusively: we must also consider the growing number of survivors of gynecological or non-gynecological cancers (breast, cervix, uterus, vagina, anus, etc.).
At a time when hormonal treatment of menopause is contested as is the installation of under urethra prosthesis, the innovation provided by the VEL technology has the merit of offering the women concerned an effective therapeutic alternative with the security of a patent. The VEL technology has an original and unique process: acting only by thermal effect and not by ablation on tissue, VEL is a safe solution in terms of side effects and potential complications. Studies have been increasing since 2012 and all demonstrate a significant improvement in the GSM signs and symptoms, as well as an improved sexual life after VEL treatment. Double-blind, placebo-controlled, randomized studies are expected in order to ultimately confirm the safety and effectivenessof VEL.
Keywords: collagen, dyspareunia, genitourinary syndrome of menopause, gynecological cancers, laser erbium Smooth®, menopause, vaginal atrophy
Received: May 31, 2019; Accepted: October 24, 2019